CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...
Phase 1
San Antonio, Texas, United States of America and 32 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
San Antonio, Texas, United States and 16 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1
San Antonio, Texas, United States and 15 other locations
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of ....
Phase 1
San Antonio, Texas, United States and 4 other locations
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors....
Phase 1
San Antonio, Texas, United States and 27 other locations
inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Ph...
Phase 1
San Antonio, Texas, United States and 63 other locations
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of CO...
Phase 1
San Antonio, Texas, United States and 8 other locations
to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combinatio...
Phase 1
San Antonio, Texas, United States and 2 other locations
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with...
Phase 1, Phase 2
San Antonio, Texas, United States of America and 11 other locations
tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors...
Phase 1
San Antonio, Texas, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal